Skip to content
Clinical Trials – home
Universitaetsklinikum Erlangen AöR
Sponsor

Universitaetsklinikum Erlangen AöR

Germany Maximiliansplatz 2, Innenstadt, 91054 Erlangen, Germany

About the sponsor

Clinical research at Universitaetsklinikum Erlangen AöR includes systemic lupus erythematosus, systemic sclerosis, idiopathic inflammatory myositis, and progressive systemic autoimmune disease resistant to B cell depletion. Additional work covers psoriatic arthritis, axial spondyloarthritis, and early rheumatoid arthritis.

  • CAR-T cell therapy for refractory autoimmune disease
  • JAK inhibition in inflammatory joint disease
  • Interleukin-targeted therapy in psoriatic arthritis
  • Immunosuppressive tapering in stable disease control

The sponsor also studies enthesitis and pain processing in inflammatory arthritis, with interest in treatment-resistant immune-mediated conditions.

About Specializations

Universitaetsklinikum Erlangen AöR runs clinical trials in conditions such as Psoriatic arthropathy, Chronic kidney disease, Systemic scleroderma, Systemic lupus erythematosus, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

13 clinical trials

Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:SP16
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Idecabtagene Vicleucel
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Oxygen
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abatacept
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:AUTOLOGOUS REGULATORY T-CELLS WITH AN IMMUNOPHENOTYPE OF CD4+CD25HI/+FOXP3+
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dacarbazine
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ixekizumab
  • Sponsor:Universitaetsklinikum Erlangen AöR
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Universitaetsklinikum Erlangen AöR

Rheumatoid arthritis

Not recruiting
Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Universitaetsklinikum Erlangen AöR

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.